Mobocertinib

Targeted TherapyApproved for: NSCLCBiomarker: EGFR Exon20 Insertion Mobocertinib (EXKIVITY) is the first oral therapy specifically designed for patients with EGFR Exon20 insertion+ NSCLC Related Research News Pre- and Post-surgical Immunotherapy-based Treatment Significantly Improved Lung Cancer OutcomesLong-term study reveals ‘ever-changing’...
|
January 5, 2022
|